TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12431929
Drug: Rectal Teaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Teaching Associate (RTA)
Study: 7161138
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 70.0 mg ascorbic acid, 2.0 mg riboflavin, and 2.0 mg pyridoxine
Study: 25915628
Drug: FRF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRF treatment at 67 °C for 3 seconds
Study: 25915628
Drug: FRF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRF treatment at 62 °C
Study: 25915628
Drug: FRF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRF treatment at 52 °C-57 °C
Study: 25915628
Drug: FRF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRF treatment at 62 °C to 67 °C
Study: 25531046
Drug: Aflibercept 6
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept 6 mg/kg plus docetaxel 75 mg/m²
Study: 25531046
Drug: Aflibercept 4
Normalized name: aflibercept 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 4 mg/kg plus docetaxel 75 mg/m²
Study: 22262486
Drug: Epoetin and
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin and oral ferrous sulfate
Study: 11784739
Drug: Scopolamine (muscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (muscarinic receptor antagonist)
Study: 9846709
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEpo) administered subcutaneously for 15 days along with iron and folic acid.
Study: 31070146
Drug: Intravenous benzylpenicillin
Normalized name: benzylpenicillin
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous benzylpenicillin
Study: 16790460
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg albendazole given twice a year as part of child health services
Study: 16790460
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg albendazole given annually as part of child health services
Study: 8917132
Drug: Serotonin selective
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin selective reuptake inhibitors (SSRIs)
Study: 2004546
Drug: Acemetacin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin (120 mg per day)
Study: 2004546
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg per day)
Study: 27084887
Drug: PACAP38 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACAP38 (all doses)
Study: 23822566
Drug: Aripiprazole once
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once monthly (400 mg)
Study: 23822566
Drug: Aripiprazole once
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once monthly
Study: 21905596
Drug: Amoxiclav (co-amoxiclav)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxiclav (co-amoxiclav) administered twice a day in 12 hour intervals
Study: 17393787
Drug: recombinant human-growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant human-growth hormone (rhGH)
Study: 8200548
Drug: Daily omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily omeprazole (20 mg every morning)
Study: 8200548
Drug: Weekend omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekend omeprazole (20 mg on three consecutive days a week)
Study: 8200548
Drug: Daily ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ranitidine (150 mg twice daily)
Study: 2828250
Drug: Sustained-release terbutaline
Normalized name: terbutaline Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release terbutaline (Bricanyl Retard) 5 mg b.i.d.
Study: 26283884
Drug: Nefopam with
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam with oxycodone 1 mg
Study: 26283884
Drug: Ketorolac with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac with oxycodone 1 mg
Study: 24142738
Drug: Batifiban coadministered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batifiban coadministered with antithrombin agents
Study: 24142738
Drug: Antithrombin agents
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin agents alone (clopidogrel, aspirin, UFH)
Study: 18460488
Drug: KGM supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: KGM supplement (1.5 g, tid)
Study: 11053315
Drug: 6% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% glucose solution (CHO trial)
Study: 9187991
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose infusion at 250 mL/hr
Study: 9187991
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose infusion at 500 mL/hr
Study: 9187991
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (no infusion)
Study: 4062714
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol powder (400 micrograms)
Study: 4062714
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol powder (200 micrograms)
Study: 31161692
Drug: Bexagliflozin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexagliflozin (20 mg)
Study: 25240757
Drug: VLP vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLP vaccines (H1 or H5) with 5-45 μg of HA/dose
Study: 22450873
Drug: 17-DMAG (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-DMAG (36 mg/m²)
Study: 19828561
Drug: cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin plus pemetrexed (CP; C, 75 mg/m(2) and P, 500 mg/m(2))
Study: 19828561
Drug: cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin plus gemcitabine (CG; C, 75 mg/m(2) and G, 1250 mg/m(2))
Study: 16969381
Drug: Hazelnut-enriched diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hazelnut-enriched diet (40 g/day)
Study: 10617168
Drug: Levodopa/benserazide 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/benserazide 100/25 mg
Study: 8932681
Drug: Doxylamine succinate
Normalized name: Doxylamine Succinate
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxylamine succinate 7.5 mg by mouth four times a day (up to nine doses)
Study: 2345835
Drug: Modifications in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modifications in organization and design of the Myocarditis Treatment Trial
Study: 7436066
Drug: Topical TAC
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TAC (tetracaine 0.5%, adrenaline 1:2,000, cocaine 11.8%)
Study: 7436066
Drug: Topical TAC
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TAC
Study: 29378197
Drug: GS-9620 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9620 (1 mg, 2 mg, and 4 mg, weekly for 12 weeks)
Study: 26200467
Drug: Presumptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presumptive treatment with ACT
Study: 24153001
Drug: Counselling (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling (monthly physical health and eating habits session)
Study: 18209140
Drug: Nasal wash
Normalized name: NASAL WASH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal wash with modified seawater solution (Physiomer) plus standard medication
Study: 16707980
Drug: Weaning products
Normalized name: Noxzema Clean Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weaning products with a mixture of GOS/FOS (4.5 g daily)
Study: 11936740
Drug: Medication monitors
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication monitors with counseling based on monitor record
Study: 11936740
Drug: Medication monitors
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication monitors without counseling based on monitor record
Study: 11936740
Drug: Simple containers
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple containers for medication
Study: 2679856
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of potent and weak corticosteroid cream with habit-reversal treatment
Study: 2679856
Drug: Corticosteroid cream
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid cream alone (control group)
Study: 30954567
Drug: 30 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 doxorubicin-loaded nanoparticles
Study: 30954567
Drug: 20 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/m2 doxorubicin-loaded nanoparticles
Study: 26943947
Drug: USL255 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: USL255 (200 mg) sprinkled onto applesauce
Study: 9464712
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (60 g daily containing 40 g isolated soy protein)
Study: 7622257
Drug: Pefloxacin (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (1,200 mg daily for 15 days)
Study: 7622257
Drug: Chloramphenicol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (2 g daily for 15 days)
Study: 31104873
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg of crystalline glucosamine sulfate once daily for 6 months
Study: 31104873
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment protocol
Study: 26193781
Drug: Quetiapine SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine SR (25-mg starting dose)
Study: 26193781
Drug: Placebo (25-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (25-mg starting dose)
Study: 24640582
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy plus oral porcine relaxin (pRLX), 20 ug b.i.d for 12 weeks
Study: 9726695
Drug: Vera/Tran (verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vera/Tran (verapamil SR 180 mg/trandolapril 1 mg)
Study: 9726695
Drug: Meto/HCTZ (metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meto/HCTZ (metoprolol 100 mg/hydrochlorothiazide 12.5 mg)
Study: 2661584
Drug: Carrier solution
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrier solution
Study: 26542501
Drug: Intracoronary application
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary application of 4 mL of bioabsorbable cardiac matrix (BCM)
Study: 22978318
Drug: CarboCarrier® insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CarboCarrier® insulin
Study: 22978318
Drug: NPH-insulin
Normalized name: Neutral Protamine Hagedorn (NPH) insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH-insulin
Study: 20102675
Drug: Self-administered Food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered Food Frequency Questionnaire (FFQ) administered twice (FFQ1 and FFQ2)
Study: 20102675
Drug: Self-administered Food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered Food Frequency Questionnaire (FFQ)
Study: 8947088
Drug: Alcohol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.5 mL x kg(‐1) body weight vodka, 40% alcohol by volume)
Study: 28778218
Drug: Matched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched treatment (MT) aimed specifically at hip strengthening
Study: 16639345
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg once daily of maraviroc
Study: 16639345
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg twice daily of maraviroc
Study: 8858671
Drug: Amoxicillin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (50 mg/kg/day divided twice daily) for 6 days
Study: 8858671
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (45 mg/kg/day divided into three doses/day) for 10 days
Study: 22337679
Drug: Paricalcitol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (2 μg/d)
Study: 10448286
Drug: 5-FU/LV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/LV plus IFN-alpha-2c (30 micrograms subcutaneously, three times weekly)
Study: 10448286
Drug: 5-FU/LV (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/LV (100 mg/m2 intravenously followed by 5-FU, 500 mg/m2 as a 1-h i.v. infusion, daily for 4 days)
Study: 6240755
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n = 32)
Study: 27505684
Drug: 1,064 nm long‐pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,064 nm long‐pulse Nd:YAG laser treatment
Study: 25369399
Drug: Group F
Normalized name: Prostaglandin group F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group F (didn't chew gum but had other parafunctional oral habits)
Study: 25369399
Drug: Group G
Normalized name: Prostaglandin group G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G (didn't have parafunctional oral habits)
Study: 20332605
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 100 mg epirubicin instillation within 6 hours after TUR-BT
Study: 20332605
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of 100 mg epirubicin instillation (second dose during 12th-18th hours after TUR-BT)
Study: 17599428
Drug: Intensive glycemia
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemia treatment arm of the ACCORD trial
Study: 1735399
Drug: 6.7 ml
Normalized name: NOXAFIL 300 MG in 16.7 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.7 ml of 0.75% bupivacaine
Study: 24382782
Drug: Recombinant interleukin-2
Normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant interleukin-2 (rIL-2) treatment for 90 days, including six courses of low-dose daily rIL-2 followed by 3-day high-dose boluses.
Study: 24382782
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no further therapy).
Study: 24382782
Drug: Recombinant interleukin-2
Normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant interleukin-2 (rIL-2) treatment for 90 days.
Study: 21993078
Drug: arzoxifene 20
Normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: arzoxifene 20 mg/d
Study: 15846259
Drug: Clopidogrel added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel added to standard fibrinolytic therapy
Study: 15846259
Drug: Standard fibrinolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fibrinolytic therapy alone (placebo control)
Study: 9708644
Drug: CE (Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE (Cyclophosphamide 4 g/m2, Etoposide 600 mg/m2, G‐CSF 6 microg/kg/day)
Study: 9708644
Drug: CEP (Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP (Cyclophosphamide 4 g/m2, Etoposide 600 mg/m2, G‐CSF 6 microg/kg/day, Cisplatin 105 mg/m2)
Study: 7893440
Drug: Retrovector-transduced autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrovector-transduced autologous fibroblasts (VTAF) administered via three intramuscular injections at 2-week intervals.
Study: 2712548
Drug: Norfloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin, 400 mg alone
Study: 2712548
Drug: Sucralfate, 1
Normalized name: Sucralfate, 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, 1 g concurrently with norfloxacin, 400 mg
Study: 2712548
Drug: Sucralfate, 1
Normalized name: Sucralfate, 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, 1 g followed by norfloxacin, 400 mg, 2 h later
Study: 11199952
Drug: Drug-free healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free healthy controls
Study: 9017356
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (99 U microcrystalline solid insulin)
Study: 9017356
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (10 U regular insulin)
Study: 3791560
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus injection of 300 mg/m2 (S arm)
Study: 3791560
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 80 mg/m2 daily for 5 days (D x 5 arm)
Study: 29654011
Drug: Multimorbidity Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimorbidity Treatment Burden Questionnaire (MTBQ)
Study: 27054932
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for mild GDM diagnosed using Carpenter-Coustan criteria
Study: 20978374
Drug: MRK adenovirus
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRK adenovirus type 5 gag/pol/nef HIV vaccine
Study: 15641767
Drug: Gene-based vaccines
Normalized name: covid-19, RNA-based vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene-based vaccines (plasmid DNA and recombinant adenoviral vector carrying human PSMA)
Study: 10484239
Drug: Lipid-regulating treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-regulating treatment
Study: 10484239
Drug: Cholesterol-lowering drug
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering drug therapy
Study: 8698614
Drug: Double-blinded capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blinded capsules containing different levels of vitamin C and beta-carotene
Study: 1928974
Drug: Inhaled SK&F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled SK&F 104353 (average nebulized dose, 893 micrograms)
Study: 25328091
Drug: Metformin powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin powder formulation
Study: 25328091
Drug: Metformin tablets
Normalized name: metformin Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin tablets formulation
Study: 19152203
Drug: Methadone doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone doses >= 60 mg/day
Study: 19152203
Drug: Flexible dosing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dosing strategies
Study: 18545119
Drug: Intravenous metamizole
Normalized name: Metamizole
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metamizole
Study: 12006728
Drug: Complementary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary treatment
Study: 2401126
Drug: 4.2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2 mg/kg/day caffeine (low dose)
Study: 2401126
Drug: 12 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/kg/day caffeine (high dose)
Study: 363334
Drug: Spironolactone 400
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 400 mg/day
Study: 363334
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydrochlorothiazide and spironolactone
Study: 363334
Drug: Spironolactone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (up to 100 mg/day)
Study: 31502382
Drug: Pylera® (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pylera® (2 capsules) plus 250 mg each of tetracycline and metronidazole, pantoprazole 20 mg b.i.d., for 10 days
Study: 31502382
Drug: Gastrus® (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrus® (2 x 10^8 CFU L reuteri DSM 17 938 plus 2 x 10^8 CFU L reuteri ATCC PTA 6475) plus 250 mg each of tetracycline and metronidazole, pantoprazole 20 mg b.i.d., for 10 days
Study: 20032538
Drug: PEG‐IFN‐alpha2a treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐alpha2a treatment
Study: 14710212
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m² and cisplatin 80 mg/m² on day 1 (DC)
Study: 14710212
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m² on day 8 and irinotecan 60 mg/m² on day 1 and 8 (DI)
Study: 9424908
Drug: Thrombin-adrenaline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin-adrenaline solution (Group I)
Study: 3284530
Drug: Thymopentin (Timunox)
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (Timunox) 1 ml (50 mg) plus lidocaine 1 ml (2%), once a week for 5 weeks
Study: 3284530
Drug: Methylprednisolone depot
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone depot 1 ml (40 mg) plus lidocaine 1 ml (2%)
Study: 29246818
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of DMPA
Study: 29246818
Drug: Clinic administration
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic administration of DMPA